Vactech
Vaccine technologies and candidates (type 1 diabetes, coeliac, asthma/allergy): flagship is a multivalent enterovirus/Coxsackie B vaccine to prevent T1D — Phase 1 human trial complete. Sole owner of the T1D vaccine patents. Univ. of Tampere virology roots (founded 2001).
The row
- Stage
- Pre-revenue — No sales yet
- Location
- Tampere
- Founded
- 2001
- Research origin
- Tampere Univ. + Univ. of Helsinki
- Business ID
- 1652703-4 · Finnish trade register
Links
Where this sits on the map
Vactech is one of 33 companies in Therapeutics & Diagnostics. The others:
How this row was decided
Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗